⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IBRX News
ImmunityBio, Inc. Common Stock
B-cell Inhibitors Market for Non-Oncology Diseases, 2026-2035 Industry Trends and Global Forecasts - Growing Prevalence of Autoimmune Disorders and Hematologic Cancers Drives Rapid Advancement
globenewswire.com
IBRX
BCRX
B-cell Inhibitors Market for Non-Oncology Diseases, 2026-2035 Industry Trends and Global Forecasts - Growing Prevalence of Autoimmune Disorders and Hematologic Cancers Drives Rapid Advancement
globenewswire.com
IBRX
ALNY
ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data
prnewswire.com
IBRX
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026
businesswire.com
IBRX
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
businesswire.com
IBRX
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
prnewswire.com
BNTX
CRSP
NVCR
IBRX
ONCY
ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit
businesswire.com
IBRX
Biotech Breakthroughs, Big Buyouts, Immunotherapy Momentum, and a Media Megamerger
globenewswire.com
ACLX
IBRX
GETY
Form 8-K
sec.gov
IBRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
accessnewswire.com
IBRX